3/18
08:40 am
xair
Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
Low
Report
Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
3/17
05:14 pm
xair
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial [Yahoo! Finance]
Low
Report
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial [Yahoo! Finance]
3/17
04:35 pm
xair
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
Low
Report
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
3/11
07:37 am
xair
Beyond Air to Participate in the 38th Annual Roth Conference in March [Yahoo! Finance]
Low
Report
Beyond Air to Participate in the 38th Annual Roth Conference in March [Yahoo! Finance]
3/11
07:00 am
xair
Beyond Air to Participate in the 38th Annual Roth Conference in March
Low
Report
Beyond Air to Participate in the 38th Annual Roth Conference in March
3/10
11:50 am
xair
Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
Low
Report
Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.
3/10
08:01 am
xair
Beyond Air halts sale of NeuroNOS subsidiary to XTL Biopharmaceuticals [Seeking Alpha]
Medium
Report
Beyond Air halts sale of NeuroNOS subsidiary to XTL Biopharmaceuticals [Seeking Alpha]
3/10
07:30 am
xair
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
Medium
Report
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
3/4
05:57 am
xair
Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies [Yahoo! Finance]
Low
Report
Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies [Yahoo! Finance]
2/25
04:42 pm
xair
How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval [Yahoo! Finance]
Medium
Report
How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval [Yahoo! Finance]
2/20
08:14 pm
xair
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ... [Yahoo! Finance]
2/20
08:00 am
xair
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
Medium
Report
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
2/13
04:46 pm
xair
Beyond Air, Inc. Q3 2026 Earnings Call Summary [Yahoo! Finance]
Low
Report
Beyond Air, Inc. Q3 2026 Earnings Call Summary [Yahoo! Finance]
2/13
10:43 am
xair
Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript [Seeking Alpha]
Neutral
Report
Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript [Seeking Alpha]
2/13
07:30 am
xair
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Medium
Report
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
2/4
08:00 am
xair
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
Low
Report
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
1/27
06:24 pm
xair
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences [Yahoo! Finance]
Medium
Report
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences [Yahoo! Finance]
1/27
04:05 pm
xair
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
Medium
Report
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
1/26
04:05 pm
xair
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
Medium
Report
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
1/21
08:00 am
xair
Beyond Air (NASDAQ:XAIR) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.
Low
Report
Beyond Air (NASDAQ:XAIR) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.
1/20
08:11 am
xair
Beyond Air (NASDAQ:XAIR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating on the stock.
High
Report
Beyond Air (NASDAQ:XAIR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating on the stock.
1/14
08:30 am
xair
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Medium
Report
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
1/13
10:34 am
xair
BC-Most Active Stocks [Yahoo! Finance]
Medium
Report
BC-Most Active Stocks [Yahoo! Finance]
1/13
07:42 am
xair
XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership [Yahoo! Finance]
High
Report
XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership [Yahoo! Finance]
1/13
07:30 am
xair
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
High
Report
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership